Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
National Institutes of Health Clinical Center (CC)
UNC Lineberger Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
Filamon LTD
Hoffmann-La Roche
Psyence Australia Pty Ltd
ViroMissile, Inc.
Erasca, Inc.
Dana-Farber Cancer Institute
Arvinas Inc.
Essen Biotech
Azienda Ospedaliero-Universitaria di Parma
MacroGenics
City of Hope Medical Center
Daiichi Sankyo
Second Life Therapeutics
City of Hope Medical Center
Mayo Clinic
Degron Therapeutics Co.
Cancer Research UK
Abramson Cancer Center at Penn Medicine
M.D. Anderson Cancer Center
Revolution Medicines, Inc.
Tempus AI
UNC Lineberger Comprehensive Cancer Center
Actym Therapeutics, Inc.
Institut Bergonié
Day One Biopharmaceuticals, Inc.
Ikena Oncology
UNC Lineberger Comprehensive Cancer Center
Memgen, Inc.
Washington University School of Medicine
Palleon Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc.
Day One Biopharmaceuticals, Inc.
Cancer Research UK
Milton S. Hershey Medical Center
University of Pittsburgh
Novartis
NGM Biopharmaceuticals, Inc
DEKA Biosciences
OncoC4, Inc.
Columbia University
Kymab Limited
Stanford University
Cedars-Sinai Medical Center
National Cancer Institute (NCI)